| December 2019 |
Genetic Tests Alert Patients to Diabetes Risk
Customers who provided DNA samples to the genetic testing company 23andMe are learning whether they may be at higher risk of developing type 2 diabetes. Current research findings highlighted in a white paper on 23andMe’s type 2 diabetes report, published in March 2019, have been generating interest in how these genetic tests may contribute to the future of healthcare diagnosis and intervention. Read more. |
|
|
Lower Weight Thresholds May Not Protect Ethnic Minorities
Big data suggests that ethnic-minority patients have a higher risk of developing diabetes at lower weights than white patients. In one of the largest studies examining the relationship between body mass index and prediabetes and diabetes, Kaiser Permanente research scientists report, the number of minority study subjects was large enough to draw conclusions that can contribute to future diabetes treatment and prevention. Here is more information. |
|
|
New Intervention Improves Glycemic Coverage
A new treatment using an artificial pancreas that automatically monitors blood-glucose levels demonstrated improved efficacy in controlling blood glucose when compared with previous usual treatment for patients diagnosed with type 1 diabetes. Findings of this multicenter, randomized clinical trial funded by the National Institutes of Health were published in the New England Journal of Medicine in late October. Here is more information. |
|
|
Connect With U.S. Pharmacist
    |
